Details of the Drug

General Information of Drug (ID: DMATJL9)

• Drug Name: SGN-B6A

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Drug Type: Antibody drug conjugate
• Cross-matching ID: TTD ID: DJYD13

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin beta-6 (ITGB6)	TTKQSXZ	ITB6_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04389632) A Study of SGN-B6A in Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Seagen.